GlassScriptPhysician profile
Brian T Pendarvis
NPI 1417952904
$519.01
in general payments reported to CMS, 2019-2025
14 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $149 · 2022: $126 · 2023: $23.09 · 2024: $73.02 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $243.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $97.53 | 2021-2025 | Repatha, Otezla |
| Lilly USA, LLC | $76.04 | 2021-2022 | |
| Astellas Pharma US INC | $61.95 | 2022 | |
| Pfizer INC. | $55.57 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.51 | 2025 | |
| Supernus Pharmaceuticals, INC. | $27.82 | 2024 | Qelbree |
| Astrazeneca Pharmaceuticals LP | $23.22 | 2024 | Breztri |
| Novo Nordisk INC | $23.09 | 2023 | Rybelsus, Ozempic |
| Abbvie INC. | $22.48 | 2022 | |
| Agile Therapeutics, INC. | $21.98 | 2024 | Twirla |
| Eisai INC. | $18.52 | 2021 | |
| Kyowa Kirin, INC. | $17.05 | 2025 | |
| Merck Sharp & Dohme LLC | $15.06 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Pendarvis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.